Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forte Biosciences, Inc.
Report date February 26, 2020 · Filed February 28, 2020
Section 16 reporting ended · disclosed 2020-02-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,685 |
Reported balance
After 2020-02-26 transaction · row 1
1 source rowRow 1 · 2020-02-26 · Grant · Acquired 13,941 · Balance 23,685 F1: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020 with acceleration of vesting to occur upon the resignation of the Reporting Person. The Reporting Person resigned on February 26, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy The Harry Edward Gruber and Joan Diane Cunningham Trust, dated 7/12/1988 | 417,753 |
Reported balance
Holding disclosure · report date 2020-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 417,753 |
Filing footnotes · ownership attribution and instrument terms
F1: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020 with acceleration of vesting to occur upon the resignation of the Reporting Person. The Reporting Person resigned on February 26, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2020 Filed Feb 28, 2020 16:32 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantCommon Stock | 13,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013879 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,685 F1 · shares: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020 with acceleration of vesting to occur upon the resignation of the Reporting Person. The Reporting Person resigned on February 26, 2020. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 20:25 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052616 · doc4.xml · derivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| May 24, 2019 Filed May 29, 2019 16:22 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 5,000 | $4.56 | $22,782.50 |
DisclosureSEC source: 0001209191-19-033184 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,744 F1 · balance_after: Includes 1,130 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 1,114 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 08, 2017 Filed Dec 14, 2017 20:51 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | OtherCommon Stock | 2,500 | $8.50 | $21,250.00 |
DisclosureSEC source: 0001209191-17-065787 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Research & Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 2,500 shares by the Reporting Person on December 8, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 26, 2017 Filed May 31, 2017 21:10 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-17-036622 · doc4.xml · derivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Research & Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 5/26/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 5/26/2017. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 17:41 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 25,000 | $10.00 | $250,000.00 |
DisclosureSEC source: 0001209191-17-027909 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Research & Devel 10b5-1 filing: Not disclosed Ownership: Indirect · By The Harry Edward Gruber and Joan Diane Cunningham Trust, dated 7/12/1988 Disclosed balance after: 417,753 F1 · kind: The shares were purchased at the Issuer's initial public offering. Read SEC document |
| April 12, 2017 Filed Apr 12, 2017 21:00 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 27,536 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026751 · doc4.xml · derivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Research & Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,536 Underlying: Common Stock · 27,536 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.